Literature DB >> 31489565

Concise Commentary: Second Line Is Not Second Best-Continuing Validity of the Oxford Criteria in the Management of Acute Severe Ulcerative Colitis.

Pauline Rivière1, David Laharie1, Philippe Marteau2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31489565     DOI： 10.1007/s10620-019-05788-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  7 in total

1.  Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis.

Authors:  S Sebastian; S Myers; S Nadir; S Subramanian
Journal:  Dig Dis Sci       Date:  2018-12-07       Impact factor: 3.199

2.  Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry.

Authors:  I Ordás; E Domènech; M Mañosa; V García-Sánchez; E Iglesias-Flores; F Rodríguez-Moranta; L Márquez; O Merino; F Fernández-Bañares; F Gomollón; M Vera; A Gutiérrez; J LLaó; J P Gisbert; M Aguas; L Arias; I Rodríguez-Lago; C Muñoz; N Alcaide; X Calvet; C Rodríguez; M A Montoro; S García; M L De Castro; M Piqueras; L Pareja; J Ribes; J Panés; M Esteve
Journal:  Am J Gastroenterol       Date:  2018-05-01       Impact factor: 10.864

3.  Predicting outcome in severe ulcerative colitis.

Authors:  S P Travis; J M Farrant; C Ricketts; D J Nolan; N M Mortensen; M G Kettlewell; D P Jewell
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

4.  Acute Severe Ulcerative Colitis: The Oxford Criteria No Longer Predict In-Hospital Colectomy Rates.

Authors:  Alice C Moore; Brian Bressler
Journal:  Dig Dis Sci       Date:  2019-05-15       Impact factor: 3.199

5.  Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.

Authors:  D Laharie; A Bourreille; J Branche; M Allez; Y Bouhnik; J Filippi; F Zerbib; G Savoye; L Vuitton; J Moreau; A Amiot; J Cosnes; E Ricart; O Dewit; A Lopez-Sanroman; M Fumery; F Carbonnel; G Bommelaer; B Coffin; X Roblin; G van Assche; M Esteve; M Farkkila; J P Gisbert; P Marteau; S Nahon; M de Vos; J Lambert; J Y Mary; E Louis
Journal:  Gut       Date:  2017-01-04       Impact factor: 23.059

6.  Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Authors:  David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann
Journal:  Lancet       Date:  2012-10-10       Impact factor: 79.321

7.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.

Authors:  Marcus Harbord; Rami Eliakim; Dominik Bettenworth; Konstantinos Karmiris; Konstantinos Katsanos; Uri Kopylov; Torsten Kucharzik; Tamás Molnár; Tim Raine; Shaji Sebastian; Helena Tavares de Sousa; Axel Dignass; Franck Carbonnel
Journal:  J Crohns Colitis       Date:  2017-07-01       Impact factor: 10.020
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.